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Psoriasis is one of the most common chronic recurrent multifactorial diseases of 
the skin with a predominance of genetic bias, characterized by hyperproliferation of 
epidermal cells, impaired keratinization due to inflammatory reaction in the dermis, 
as well as the lesions of nails and joints. According to the results of clinical and 
epidemiological studies, about 3-4% of the population of our planet, regardless of 
gender, age and ethnic group, suffers from psoriasis [2,15]. However, despite the 
considerable spread of psoriasis and a large amount of research on this problem, there 
is still no single view of the pathogenesis of this dermatosis. In order to objectively 
understand the pathogenesis of psoriasis, it is necessary to take into account the 
understudied comorbidity of this disease. 
Recently, an indisputable link between psoriasis and obesity has been proven 
[9,12]. Alimentary obesity develops as a result of metabolic and eating behavior 
disorders. It is characterized by the accumulation of adipose tissue in the body. 
Obesity can be both an independent multifactorial disease – primary obesity 
(alimentary-constitutional), and a syndrome that accompanies the course of other 
diseases – secondary obesity (symptomatic) [14]. In the structure of morbidity, 
primary obesity occurs in 95% of patients, secondary – only in 5% [7,12]. The main 
etiological reason for the development of primary obesity is the alimentary factor. 
The inhabitants of developed countries are currently the hostages of readily available 
food. In this context, the food moves from the category of necessity to the category of 
pleasure. Thus, eating disorders are gradually formed, which anticipates the 
development of obesity. Most often, obesity occurs as a result of consuming foods of 
high energy value (caloric content) in combination with insufficient physical activity 
and a factor of genetic susceptibility. However, in isolated cases, the occurrence of 
the disease against the background of genetic endocrine disruptions or malignancies 
was observed. A person is considered obese if the body mass index (BMI) exceeds 30 
THEORETICAL FOUNDATIONS FOR THE IMPLEMENTATION AND 
ADAPTATION OF SCIENTIFIC ACHIEVEMENTS IN PRACTICE 
101 
kg / m². Obesity has been found to increase the risk of many diseases, including 
psoriasis, contributing to its severe course with prolonged periods of relapse, which 
are poorly treated with standard therapy. In contrast, weight loss leads to a more 
favorable course of dermatosis [14]. The literature has broadly covered the issue of 
identical pathogenetic mechanisms of inflammatory processes in psoriasis and 
obesity, which form a vicious circle at the level of the immune system, which must be 
broken in order to treat these diseases successfully. Therefore, further study of the 
comorbidity of psoriatic disease and obesity makes it possible to identify new target 
therapies to prevent complications and develop a more effective treatment of this 
pathology [E]. 
The aim of the research is to study the features of the clinical course of psoriasis 
in patients with grade I-II alimentary obesity. 
Materials and methods. 
The study group consisted of 80 patients with advanced uncomplicated plaque 
psoriasis, progressive stage, moderate severity with concomitant grade I-II alimentary 
obesity, 51 (64%) men, and 29 (36%) women aged from 35 to 65 years. 
To identify the features of the clinical course of psoriasis combined with grade I-
II alimentary obesity, as a control for comparison of the studied parameters, we 
selected a group of patients, consisting of 20 persons of the appropriate age (8 women 
and 12 men), patients with common, vulgar psoriasis of moderate severity, 
progressive stage of the course with normal body weight. 
The Psoriatic Area and Severity Index [4] was used to assess the severity of 
psoriasis. 
To determine the impact of skin rashes on the quality of patients’ life, we used the 
DLQI (Dermatology Life Quality Index) questionnaires for assessment of the quality 
of life of dermatological patients [9]. 
To assess the severity of alimentary obesity, we determined body mass index 
(BMI) [10]. The study included individuals with a BMI of 30-40 kg / m². 
The volume of laboratory studies included the use of conventional methods of 
general clinical and biochemical blood tests, taken in the morning on an empty 
stomach. Studies of lipid metabolism were performed by estimating the level of total 
cholesterol (TC) and triglycerides (TG). The concentration of cholesterol in the 
composition of very-low-density lipoproteins (VLDL cholesterol) was determined by 
the ratio TG / 22.5. Dyslipidemia was diagnosed when the level of TC was greater 
than 5.2 mmol / l, triglycerides higher than 1.7 mmol / l, VLDL less than 1.0 mmol / 
l. The parameters were evaluated according to the criteria of the US National 
Cholesterol Education Program [13]. 
The statistical processing of the results was performed using Statistica 7.0. The 
difference was considered reliable with a probability of error p <0.05. 
Results of the research 
In all patients, the clinical presentation of the disease was studied, anthropometric 
parameters were measured, the grade of obesity by BMI was determined, the history 
of life and disease was analyzed, and clinical and biochemical blood tests were 
conducted. 
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Based on the clinical presentation of psoriatic lesions, the PASI index was 
calculated, reflecting the area, color intensity, infiltration, and desquamation of 
psoriatic rash. Analyzing the results, it was found that the average group PASI index 
in patients with psoriasis and concomitant grade I-II alimentary obesity was - (21.8 ± 
1.4), and in patients with psoriasis without obesity - (15.2 ± 1.2). The obtained results 
correspond to the average severity of psoriasis in both groups of patients. However, it 
should be noted that the average group PASI index was 30.3% higher in the group of 
patients with concomitant grade I-II alimentary obesity. The difference in PASI 
indexes depended on the severity of infiltration and hyperemia, while the area and 
intensity of psoriatic rash were approximately the same. Thus, in patients with 
psoriasis and concomitant grade I-II alimentary obesity, psoriatic rashes had a 
stagnant-red color with pronounced infiltration, whereas in patients without obesity, 
rashes had a pink color with less pronounced infiltration phenomena. 
All patients complained of sleep disturbance, unrest, and anxiety, which resulted 
in poor quality of life. To study the impact of the disease on the patient’s quality of 
life, we calculated the dermatological quality of life index (DLQI). Analyzing the 
results of the study, it was found that in patients with psoriasis and concomitant grade 
I-II alimentary obesity, the DLQI index was 20.3 ± 0.5 points, whereas in patients 
without obesity it was 14.5 ± 0.4 points, which indicates the pronounced impact of 
the disease on the quality of life for patients in both groups. It should be noted that 
the average group DLQI index is by 28.6% higher in the group of patients with 
concomitant grade I-II alimentary obesity. 
In the examination of patients who made up the study group and BMI calculation 
according to the classification of obesity, it was found that 29 (36.25%) patients had 
grade I obesity (average group BMI - 34.04 kg / m²), grade II obesity - 51 (63.75%) 
patients (average group BMI - 38.15 kg / m²). The average BMI in the control group 
of patients with normal body weight was 24.5 kg / m², which is by 35.8% lower than 




Clinical and anthropometric parameters of the examined patients (М±m) 
Indicator 
Value   
Study group (n=80) Control group (n=20) 
PASI (points) 21.8±1.41.2±15.2 ٭ 
DLQI (points) 20.3±0.60.7±14.5 ٭ 
BMI (kg/m²) Value (number of patients) 
Normal weight 0 24.5 (20) 
grade І obesity 34.04 (29) 0 
grade ІІ obesity 38.15 (51) 0 
Number of psoriasis relapses: Number of patients 
Once a year 0 6 
2 times a year 0 12 
3 times a year 13 2 
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4 times a year 67 0 
 
In order to evaluate metabolic disorders in patients with psoriasis and 
concomitant grade I-II alimentary obesity, we conducted studies of general and 
biochemical blood tests (Tables 2). 
 
Table No. 2. 




Patients with psoriasis 
with grade І-ІІ obesity 
(n=80) 
Patients with psoriasis 
without obesity (n=20) 
Hemoglobin, (g/l) 
Men – 130-160 
Women – 120-140 
128.5±5.8 147.3±6.5 
Erythrocytes, (10⁹/l) 
Men – 4.5-5.0 
Women – 4.0-4.5 
4.2±0.4 4.6±0.5 
Color index 0.85-1.1 0.93±0.09 1.2±0.1 
Leukocytes, (10⁹/l) 4.0-9.0 7.2±1.3 5.2±1.2 
Stab neutrophils, (%) 1.0-6.0 1.53±0.21 2.4±0.35 
Segmented neutrophils, (%) 47.0-72.0 63.25±3.1 65.8±3.2 
Eosinophils, (%) 0.5-5.0 3.8±1.2 2.5±0.7 
Basophils, (%)  0-1.0 9.0±0.2 0.7±0.4 
Lymphocytes, (%) 19.0-37.0 26.73±2.62 20.1±1.9 
Monocytes, (%) 3.0-10.0 4.65±0.58 5.3±0.73 
ESR, (mm/h) 2-15 11.5±1.11.0±7.3 ٭ 
Note: ٭ The probability of error of differences p˂0.05 
It can be noted that the level of all indicators is within the norm, both in patients 
with psoriasis and concomitant grade I-II alimentary obesity and in patients with 
psoriasis and normal body weight. However, it should be noted that in general blood 
analysis of patients with psoriasis and concomitant grade I-II alimentary obesity, we 
revealed moderate differences, characterized by a decrease in the amount of 
hemoglobin by 12.8%, the total number of erythrocytes by 8.7%, CI by 5%, stab and 
segmented neutrophils by 36.3% and 3.9% respectively, monocytes by 12.3%, and 
leukocytes increase by 38.5%, eosinophilia by 52%, basophils by 28.6%, 
lymphocytes by 33% and an increase in ESR by 57.5% as compared to the rates of 
patients with psoriasis and normal weight. 
When analyzing the data of biochemical blood analysis in patients with psoriasis 
with concomitant grade I-II alimentary obesity, significant differences were found in 
comparison with patients with psoriasis without obesity. Thus, in patients with 
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psoriasis with concomitant grade I-II alimentary obesity, there was an increase in 
glucose by 10%, total cholesterol by 44.2%, triglycerides by 60% and LDL by 36%, 
as well as a decrease in HDL by 4.6%, total protein by 10.5% as compared to patients 
with normal body weight psoriasis, indicating impaired hepatic function by reducing 
the total protein and disrupted lipid metabolism with the effects of 
dyslipoproteinemia, characterized by an increase in the content of total cholesterol, 
LDL, triglycerides, decreased HDL levels. It should be noted that in patients with 
psoriasis with concomitant grade I-II alimentary obesity, there were more significant 
disruptions of the above indicators. Thus, the study found that patients with psoriasis 
with concomitant grade I-II alimentary obesity have a more severe course of 
dermatosis as compared to patients with psoriasis with normal body weight, which is 
well observed by the PASI and DLQI of patients and the incidence of psoriasis 
exacerbations. 
Conclusions 
Alimentary obesity in patients with psoriasis leads to metabolic disorders, 
complicating the course of dermatosis and worsening the patient's DLQI, leading to 
inefficiency of standard methods of therapy and frequent exacerbations of psoriatic 
disease. 
References  
1. Yemchenko Ya.  PPAR-Gamma agonist pioglitazone reduced CD68+ but not 
CD163+ macrophage dermal infiltration in obese psoriatic patients / Ya. O. 
Yemchenko, V. I. Shynkevych, K. Ye Ishcheikin, I. P. Kaidashev // Hindawi. – 2020. 
– С. 1–6.  
2. Емченко Я. А. Особенности клинического течения псориаза у больных с 
сопутствующим метаболическим синдромом в зависимости от уровня 
системного воспаления / Я. А. Емченко // Georgian Medical News. – 2014. – № 11 
(236). – Р. 43–47.Yemchenko Ya, Ishcheikin K. Deiaki spilni aspekty patohenezu 
psoriazu ta metabolichnoho syndromu. Svit medytsyny ta biolohi [Some common 
aspects of the pathogenesis of psoriasis and metabolic syndrome]. 2013; № 1:176-
180. (Ukrainian). 
3. Atkinson RL. Could viruses contribute to the worldwide epidemic of obesity 
Int J Pediat Obes. 2008; 3: Suppl 1: 37-43. 
4. Kaydashev IP. Izmenenie obraza zhizni, narushenie energeticheskogo 
metabolizma i sistemnoe vospalenie kak faktory razvitiya bolezney civilizacii 
[Lifestyle changes, impaired energy metabolism and systemic inflammation as 
factors for the development of civilization diseases]. Ukraїns'kiy medichniy chasopis. 
2013; 5: 103-108. (Ukrainian). 
7. Babak OYa, Yarmish NV, Shkol'nik VV. Ozhirіnnya yak puskoviy mehanіzm 
adipocitokіnovogo kaskadu [Obesity as a trigger mechanism of the adipocytokine 
cascade]. Medicina transportu Ukrainy. 2012; 2: 94-99. (Ukrainian). 
5. Ємченко Я. О. Ожиріння як коморбідний стан при псоріазі / Я. О. 
Ємченко // Актуальні проблеми сучасної медицини: Вісник Української 
медичної стоматологічної академії. – 2018. – Т. 18, вип. 3 (63). – С. 314–319. 
6. Fredriksson, T., U. Pettersson. Severe psoriasis—oral therapy with a new 
THEORETICAL FOUNDATIONS FOR THE IMPLEMENTATION AND 
ADAPTATION OF SCIENTIFIC ACHIEVEMENTS IN PRACTICE 
105 
retinoid. Dermatologica, 1978, 157(4):238-44. PMID 357213. 
7. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute 
(NHLBI). The practical guide: identification, evaluation, and treatment of overweight 
and obesity in adults. Bethesda: National Institutes of Health. 2000, NIH publication 
00-4084. 
8. Ємченко Я. О. Роль PPAR в патогенезі псоріазу та ожиріння / Я. О. 
Ємченко // Актуальні проблеми сучасної медицини: Вісник Української 
медичної стоматологічної академії. – 2019. – № 2 (66). – С. 224–229. 
9. Yemchenko Ya.  PPAR-Gamma agonist pioglitazone reduced CD68+ but not 
CD163+ macrophage dermal infiltration in obese psoriatic patients / Ya. O. 
Yemchenko, V. I. Shynkevych, K. Ye Ishcheikin, I. P. Kaidashev // Hindawi. – 2020. 
– С. 1–6.  
10. Ємченко Я. О. Роль локального запалення в імунопатогенезі псоріазу / 
Я. О. Ємченко // Актуальні проблеми сучасної медицини: Вісник Української 
медичної стоматологічної академії. – 2019. – Т. 19, вип. 1 (65). – С. 109–114. 
11. Ємченко Я. О. Доцільність застосування піоглітазону в комплексному 
лікуванні псоріазу у хворих з надлишковою масою тіла / Я. О. Ємченко, К. Є. 
Іщейкін, І. П. Кайдашев // Вісник проблем біології і медицини. – 2019 – Вип. 2, 
т. 1 (150). – С. 18–21. 
12. Безега О.В. Досвід застосування Ресвератролу в комплексному лікуванні 
хворих на псоріаз / О. В. Безега, І. Б. Попова, К. В. Васильєва [та ін.] // 
Дерматовенерология Косметология Сексопатология. – 2019. – Вип. 3–4. – С. 
58–64. 
13. Безега О.В. Вплив антиоксидантної терапії на тяжкість перебігу, 
ефективність лікування та тривалість ремісії у хворих на псоріаз / О. В. Безега, 
І. Б. Попова // Актуальні проблеми сучасної медицини: Вісник Української 
медичної стоматологічної академії. – 2019. – Т. 19, вип 2 (66). – С. 4–8. 
14. Безега О.В. Клінічна та морфологічна обґрунтованість необхідності 
застосування вузькохвильової ультрафіолетової терапії для підвищення якості 
лікування та тривалості ремісії у хворих на псоріаз / О. І. Гладков, І. Б. Попова, 
К. В. Васильєва [та ін.] // Дерматовенерология Косметология Сексопатология. – 
2019. – Вип. 3–4. – С. 53–57. 
